Dr. Jiang Shan | Cancer Treatment | Best Researcher Award
Dr. Jiang Shan | Cancer Treatment | Harbin Medical University | China
Dr. Jiang Shan, an accomplished radiation oncologist and medical scientist at Harbin Medical University Cancer Hospital, is recognized for his pioneering contributions to nuclear medicine, radiation oncology, and nanomaterial-assisted cancer therapy. Holding a Ph.D. in Nuclear Medicine and Radiation Therapy from Harbin Medical University and a Master’s degree in Medical Dosimetry from John Patrick University, Dr. Jiang combines a deep understanding of clinical oncology with cutting-edge research on tumor biology and targeted therapies. He has served as a staff scientist and researcher in the Department of Radiation Oncology at Harbin Medical University Cancer Hospital, where he focuses on integrating molecular sensing, photothermal therapy, and radiopharmaceuticals for improved cancer diagnostics and treatments. His professional experience also includes international academic exposure as a visiting scholar at the Swedish Cancer Institute (Seattle, USA), City of Hope Medical Center (Duarte, USA), and Fudan Tumor Hospital (Shanghai, China), where he gained valuable insight into global radiotherapy advancements. Dr. Jiang’s research interests center on developing nanotechnology-based drug delivery platforms, investigating radio-resistance mechanisms in differentiated thyroid and breast cancers, and exploring hybrid photothermal–radiation therapy for multidrug-resistant tumors. His research skills encompass advanced cell culture and animal modeling, in vivo tumor imaging, photothermal and radiotherapy experimentation, and bioinformatics-based molecular data analysis. Proficient in computational tools such as GraphPad, Orange, and MS Office, he effectively bridges experimental data with clinical translation.
Selected Publications
-
Jiang, S., Hong, Z., Wu, Q., Rouhan, A., Wang, Z., & Ma, T. (2025). Gadd45B deficiency drives radio-resistance in BRAFV600E-mutated differentiated thyroid cancer by disrupting iodine metabolic genes. Cancers, 17(19), Article 3201. (Citations: 22)
-
Fu, J., Song, C., Jiang, S., Yang, S., Wu, Q., & Li, B. (2025). Drug delivery platform targeting MMP9 in combination with photothermal therapy to improve tumor chemosensitivity. Advanced Healthcare Materials, 14(5), Article 174. (Citations: 35)
-
Song, C., Guan, X., Xie, C., Jiang, S., Wu, Q., & Ma, T. (2024). Inhibiting PI3K/AKT/mTOR signaling by metal-organic frameworks for overcoming multiple drug resistance in chemoradiotherapy. Science China Materials, 67(5), 2774–2789. (Citations: 41)
-
Liu, Z., Jiang, S., Tian, Y., Shang, H., Chen, K., & Cheng, W. (2022). Targeted phototherapy by niobium carbide for mammalian tumor models similar to humans. Frontiers in Oncology, 12, 827171. (Citations: 58)
-
Jiang, S., Liu, Z., Tian, Y., Zhuang, M., Gao, Y., & Hu, H. (2021). A comprehensive evaluation of ZrC nanoparticle in combined photothermal and radiation therapy for treatment of triple-negative breast cancer. Frontiers in Oncology, 11, 801352. (Citations: 76)